Fig. 6. Nuplazid inhibits the growth of esophageal cancer patient-derived xenograft tumours in vivo.
a The photograph showed tumour tissues from PDX mice treated with solvent or Nuplazid (11 mg/kg or 44 mg/kg). b Tumour volumes were measured every 3 days. c After sacrificing, isolated tumours were weighted. d Data recorded tumour size of individual mice. Immunohistochemistry analysed the level of ki67 (e) and p-MAPK1T185/Y187 (f) in tumour tissues from treated or untreated groups of mice. All data are shown as means ± S.D. The asterisks (*, **, ***) indicate a significant decrease (p < 0.05, p < 0.01, p < 0.001, respectively).